Check out what some of your colleagues tweeted about during the EAU 2014 Annual Congress.
EAU Congress Annual Meeting Coverage
Study documents a drop in the incidence of de novo metastatic PCa from 1980 to 2011 in the United States.
Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.
In a large international trial, pre-biopsy MRI scans spared 28% of men from having to undergo a biopsy and resulted in a lower detection of clinically insignificant cancers vs standard biopsy.
Patients with longer hospital stays and pre-discharge complications were at increased risk of readmission within 30 days of discharge.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Study finds no difference in metastasis-free survival observed after 15 years compared with radiation therapy or radical prostatectomy.
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
In a small study, the treatment was associated with a 4-fold increase in average ejaculation time.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
Researchers observe benefit in prostate cancer patients with 2 or more adverse pathologic features.
Pelvic lymph node dissection in high-risk patients is 2.5 times more likely in those undergoing open rather than robotic-assisted surgery.
Men with non-palpable tumors had a 46% lower risk of positive surgical margins.
Parenteral testosterone undecanoate over 5 years found to decrease waist circumference and improve components of metabolic syndrome.
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
Risk is not eliminated if patients have risk factors for chronic kidney disease, such as hypertension and diabetes.
Patients are more than 9 times more likely to die from causes other than PCa, a new study shows.
It is associated with a 34.7% decrease in biochemical recurrence after radical prostatectomy versus patients with blood type A.
One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)